Mocht u kanker-actueel de moeite waard vinden en ons willen ondersteunen om kanker-actueel online te houden dan kunt u ons machtigen voor een periodieke donatie via donaties: https://kanker-actueel.nl/NL/donaties.html of doneer al of niet anoniem op - rekeningnummer NL79 RABO 0372931138 t.n.v. Stichting Gezondheid Actueel in Amersfoort. Onze IBANcode is NL79 RABO 0372 9311 38
Elk bedrag is welkom. En we zijn een ANBI instelling dus uw donatie of gift is in principe aftrekbaar voor de belasting.
En als donateur kunt u ook korting krijgen bij verschillende bedrijven:
7 oktober 2016: Bron: verschillende studies
Dat een gezonde leefstijl met veel bewegen en specifieke voeding en bepaalde voedingstoffen positieve effecten heeft bij het voorkomen van prostaatkanker of een recidief ervan en als aanvulling bij reguliere behandelingen is al veel over bekend. Zie in gerelateerde artikelen of zie onze literatuurlijst specifiek gerelateerd aan prostaatkanker.
Recent zijn een paar grote review studies verschenen die m.i. een mooi overzicht geven over een aantal specifieke voedingstoffen en beweging in relatie tot prostaatkanker en hormoontherapie.
7 oktober 2016: Ik had deze vergeten: A systematic review of dietary, nutritional, and physical activity interventions for the prevention of prostate cancer progression and mortality
maar is een interessante rewiewstudie over 44 gerandomiseerde studies met mooie verwijzingen naar studies gedaan met niet-toxische stoffen. Meer studies onder foto
Bron: http://www.dotcomwomen.com/fitness/should-you-get-hormone-therapy/21347/
Bv. deze studie of is eigenlijk meer een boekwerk:
Prostate Cancer, Nutrition, and Dietary Supplements (PDQ®)
Bovenstaande is een patientenversie met ook vragen die korte maar heldere antwoorden geven. En per behandelde voedingsstof een uitstekende referentielijst
En deze is de versie voor zorgprofessionals:
Prostate Cancer, Nutrition, and Dietary Supplements (PDQ®)
Een andere review studie is deze:
Integrating diet and exercise into care of prostate cancer patients on androgen deprivation therapy
Abstract met referentielijst staat hier:
Exercise, diet, and nutritional supplementation interventions have the potential to provide effective, accessible, and relatively inexpensive strategies for mitigating ADT-associated toxicities without introducing additional adverse effects.
Res Rep Urol. 2016; 8: 133–143.
Published online 2016 Aug 16. doi: 10.2147/RRU.S107852
PMCID: PMC4993404
Integrating diet and exercise into care of prostate cancer patients on androgen deprivation therapy
Abstract
Improved diagnosis and treatment regimens have resulted in greater longevity for men with prostate cancer. This has led to an increase in both androgen deprivation therapy (ADT) use and duration of exposure, and therefore to its associated adverse effects, such as sexual dysfunction, osteoporosis, reduced muscle mass, increased fat mass, and increased incidence of cardiovascular disease and type 2 diabetes. Given that the adverse effects of ADT are systemic, often debilitating, and difficult to treat, efforts continue in the development of new strategies for long-term management of prostate cancer. The PubMed database was searched to select trials, reviews, and meta-analyses in English using such search terms as “prostate cancer” and “androgen deprivation therapy”, “cardiovascular risk”, “lean body mass”, “exercise”, and “diet”. The initial searches produced 379 articles with dates 2005 or more recent. Articles published after 2004 were favored. This review utilizes the latest data to provide a status update on the effects of exercise and diet on patients with prostate cancer, focusing on ADT-associated side effects, and it discusses the evidence for such interventions. Since the evidence of large-scale trials in patients with prostate cancer is missing, and an extrapolation of supporting data to all patient subgroups cannot be provided, individualized risk assessments remain necessary before the initiation of exercise and diet programs. Exercise, diet, and nutritional supplementation interventions have the potential to provide effective, accessible, and relatively inexpensive strategies for mitigating ADT-associated toxicities without introducing additional adverse effects
References
1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108. [PubMed]
2. DeSantis CE, Lin CC, Mariotto AB, et al. Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin. 2014;64(4):252–271. [PubMed]
3. Keating NL, O’Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol. 2006;24(27):4448–4456. [PubMed]
4. Lu-Yao GL, Albertsen PC, Moore DF, et al. Survival following primary androgen deprivation therapy among men with localized prostate cancer. JAMA. 2008;300(2):173–181. [PMC free article] [PubMed]
5. Mottet N, Bellmunt J, Bolla M, et al. EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol. 2011;59(4):572–583. [PubMed]
6. Perlmutter MA, Lepor H. Androgen deprivation therapy in the treatment of advanced prostate cancer. Rev Urol. 2007;9(Suppl 1):S3–S8. [PMC free article] [PubMed]
7. Sharifi N, Gulley JL, Dahut WL. Androgen deprivation therapy for prostate cancer. JAMA. 2005;294(2):238–244. [PubMed]
8. Sharifi N, Gulley JL, Dahut WL. An update on androgen deprivation therapy for prostate cancer. Endocr Relat Cancer. 2010;17(4):R305–R315. [PMC free article] [PubMed]
9. Ahmadi H, Daneshmand S. Androgen deprivation therapy: evidence-based management of side effects. BJU Int. 2013;111(4):543–548. [PubMed]
10. Cheung AS, Zajac JD, Grossmann M. Muscle and bone effects of androgen deprivation therapy: current and emerging therapies. Endocr Relat Cancer. 2014;21(5):R371–R394. [PubMed]
11. Nguyen PL, Alibhai SM, Basaria S, et al. Adverse effects of androgen deprivation therapy and strategies to mitigate them. Eur Urol. 2015;67(5):825–836. [PubMed]
12. Van Poppel H, Tombal B. Cardiovascular risk during hormonal treatment in patients with prostate cancer. Cancer Manag Res. 2011;3:49–55. [PMC free article] [PubMed]
13. Tunn U. The current status of intermittent androgen deprivation (IAD) therapy for prostate cancer: putting IAD under the spotlight. BJU Int. 2007;99(Suppl 1):19–22. discussion 23–14. [PubMed]
14. Gruca D, Bacher P, Tunn U. Safety and tolerability of intermittent androgen deprivation therapy: a literature review. Int J Urol. 2012;19(7):614–625. [PubMed]
15. Grundy SM, Benjamin IJ, Burke GL, et al. Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation. 1999;100(10):1134–1146. [PubMed]
16. Centers for Disease Control and Prevention . A Report of the Surgeon General: Physical Activity and Health. Atlanta (GA): US Department of Health and Human Services; 1996. [Accessed March 3, 2016]. Available from: www.cdc.gov/nccdphp/sgr/pdf/sgrfull.pdf.
17. Kenfield SA, Stampfer MJ, Giovannucci E, Chan JM. Physical activity and survival after prostate cancer diagnosis in the health professionals follow-up study. J Clin Oncol. 2011;29(6):726–732. [PMC free article] [PubMed]
18. Moyad MA, Roach M., 3rd Promoting wellness for patients on androgen deprivation therapy: why using numerous drugs for drug side effects should not be first-line treatment. Urol Clin North Am. 2011;38(3):303–312. [PubMed]
19. Demark-Wahnefried W, Morey MC, Sloane R, et al. Reach out to enhance wellness home-based diet-exercise intervention promotes reproducible and sustainable long-term improvements in health behaviors, body weight, and physical functioning in older, overweight/obese cancer survivors. J Clin Oncol. 2012;30(19):2354–2361. [PMC free article] [PubMed]
20. Morey MC, Snyder DC, Sloane R, et al. Effects of home-based diet and exercise on functional outcomes among older, overweight long-term cancer survivors: RENEW: a randomized controlled trial. JAMA. 2009;301(18):1883–1891. [PMC free article] [PubMed]
21. Ainsworth BE, Haskell WL, Herrmann SD, et al. 2011 Compendium of Physical Activities: a second update of codes and MET values. Med Sci Sports Exerc. 2011;43(8):1575–1581. [PubMed]
22. Lee IM, Sesso HD, Paffenbarger RS., Jr A prospective cohort study of physical activity and body size in relation to prostate cancer risk (United States) Cancer Courses Control. 2001;12(2):187–193. [PubMed]
23. Patel AV, Rodriguez C, Jacobs EJ, Solomon L, Thun MJ, Calle EE. Recreational physical activity and risk of prostate cancer in a large cohort of U.S. men. Cancer Epidemiol Biomark Prev. 2005;14(1):275–279. [PubMed]
24. Gardner JR, Livingston PM, Fraser SF. Effects of exercise on treatment-related adverse effects for patients with prostate cancer receiving androgen-deprivation therapy: a systematic review. J Clin Oncol. 2014;32(4):335–346. [PubMed]
25. Hansen PA, Dechet CB, Porucznik CA, LaStayo PC. Comparing eccentric resistance exercise in prostate cancer survivors on and off hormone therapy: a pilot study. PM R. 2009;1(11):1019–1024. [PubMed]
26. Segal RJ, Reid RD, Courneya KS, et al. Resistance exercise in men receiving androgen deprivation therapy for prostate cancer. J Clin Oncol. 2003;21(9):1653–1659. [PubMed]
27. Bourke L, Doll H, Crank H, Daley A, Rosario D, Saxton JM. Lifestyle intervention in men with advanced prostate cancer receiving androgen suppression therapy: a feasibility study. Cancer Epidemiol Biomark Prev. 2011;20(4):647–657. [PubMed]
28. Galvão DA, Taaffe DR, Spry N, Joseph D, Newton RU. Combined resistance and aerobic exercise program reverses muscle loss in men undergoing androgen suppression therapy for prostate cancer without bone metastases: a randomized controlled trial. J Clin Oncol. 2010;28(2):340–347. [PubMed]
29. Hanson ED, Sheaff AK, Sood S, et al. Strength training induces muscle hypertrophy and functional gains in black prostate cancer patients despite androgen deprivation therapy. J Gerontol A Biol Sci Med Sci. 2013;68(4):490–498. [PMC free article] [PubMed]
30. Culos-Reed SN, Robinson JW, Lau H, et al. Physical activity for men receiving androgen deprivation therapy for prostate cancer: benefits from a 16-week intervention. Support Care Cancer. 2010;18(5):591–599. [PubMed]
31. Santa Mina D, Alibhai SM, Matthew AG, et al. A randomized trial of aerobic versus resistance exercise in prostate cancer survivors. J Aging Phys Act. 2013;21(4):455–478. [PubMed]
32. Culos-Reed SN, Robinson JL, Lau H, O’Connor K, Keats MR. Benefits of a physical activity intervention for men with prostate cancer. J Sport Exerc Psychol. 2007;29(1):118–127. [PubMed]
33. Segal RJ, Reid RD, Courneya KS, et al. Randomized controlled trial of resistance or aerobic exercise in men receiving radiation therapy for prostate cancer. J Clin Oncol. 2009;27(3):344–351. [PubMed]
34. Cella D. The Functional Assessment of Cancer Therapy-Anemia (FACT-An) Scale: a new tool for the assessment of outcomes in cancer anemia and fatigue. Semin Hematol. 1997;34(3 Suppl 2):13–19. [PubMed]
35. Yellen SB, Cella DF, Webster K, Blendowski C, Kaplan E. Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system. J Pain Symptom Manage. 1997;13(2):63–74. [PubMed]
36. Cormie P, Newton RU, Spry N, Joseph D, Taaffe DR, Galvao DA. Safety and efficacy of resistance exercise in prostate cancer patients with bone metastases. Prostate Cancer Prostatic Dis. 2013;16(4):328–335. [PubMed]
37. O’Neill RF, Haseen F, Murray LJ, O’Sullivan JM, Cantwell MM. A randomised controlled trial to evaluate the efficacy of a 6-month dietary and physical activity intervention for patients receiving androgen deprivation therapy for prostate cancer. J Cancer Surviv. 2015;9(3):431–440. [PubMed]
38. Cormie P, Galvao DA, Spry N, et al. Can supervised exercise prevent treatment toxicity in patients with prostate cancer initiating androgen-deprivation therapy: a randomised controlled trial. BJU Int. 2015;115(2):256–266. [PubMed]
39. Hasenoehrl T, Keilani M, Sedghi Komanadj T, et al. The effects of resistance exercise on physical performance and health-related quality of life in prostate cancer patients: a systematic review. Support Care Cancer. 2015;23(8):2479–2497. [PubMed]
40. Keating NL, O’Malley AJ, Freedland SJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. J Natl Cancer Inst. 2010;102(1):39–46. [PMC free article] [PubMed]
41. FDA drug safety communication: update to ongoing safety review of GnRH agonists and notification to manufacturers of GnRH agonists to add new safety information to labeling regarding increased risk of diabetes and certain cardiovascular diseases. Silver Spring (MD): US Food and Drug Administration; 2010. [Accessed April 29, 2016]. Available from: http://www.fda.gov/Drugs/DrugSafety/ucm229986.htm.
42. Efstathiou JA, Bae K, Shipley WU, et al. Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85-31. J Clin Oncol. 2009;27(1):92–99. [PMC free article] [PubMed]
43. Blair SN, Jackson AS. Physical fitness and activity as separate heart disease risk factors: a meta-analysis. Med Sci Sports Exerc. 2001;33(5):762–764. [PubMed]
44. Fagard RH. Exercise characteristics and the blood pressure response to dynamic physical training. Med Sci Sports Exerc. 2001;33(6 Suppl):S484–S492. discussion S493–S494. [PubMed]
45. Leon AS, Rice T, Mandel S, et al. Blood lipid response to 20 weeks of supervised exercise in a large biracial population: the HERITAGE Family Study. Metabolism. 2000;49(4):513–520. [PubMed]
46. Thompson PD, Buchner D, Pina IL, et al. Exercise and physical activity in the prevention and treatment of atherosclerotic cardiovascular disease: a statement from the Council on Clinical Cardiology (Subcommittee on Exercise, Rehabilitation, and Prevention) and the Council on Nutrition, Physical Activity, and Metabolism (Subcommittee on Physical Activity) Circulation. 2003;107(24):3109–3116. [PubMed]
47. Rafieian-Kopaei M, Setorki M, Doudi M, Baradaran A, Nasri H. Atherosclerosis: process, indicators, risk factors and new hopes. Int J Prev Med. 2014;5(8):927–946. [PMC free article] [PubMed]
48. Ridker PM. LDL cholesterol: controversies and future therapeutic directions. Lancet. 2014;384(9943):607–617. [PubMed]
49. Galvão DA, Spry NA, Taaffe DR, et al. Changes in muscle, fat and bone mass after 36 weeks of maximal androgen blockade for prostate cancer. BJU Int. 2008;102(1):44–47. [PubMed]
50. Greenspan SL, Coates P, Sereika SM, Nelson JB, Trump DL, Resnick NM. Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer. J Clin Endocrinol Metab. 2005;90(12):6410–6417. [PubMed]
51. Morote J, Morin JP, Orsola A, et al. Prevalence of osteoporosis during long-term androgen deprivation therapy in patients with prostate cancer. Urology. 2007;69(3):500–504. [PubMed]
52. Ebeling PR. Clinical practice. Osteoporosis in men. N Engl J Med. 2008;358(14):1474–1482. [PubMed]
53. Hamilton EJ, Ghasem-Zadeh A, Gianatti E, et al. Structural decay of bone microarchitecture in men with prostate cancer treated with androgen deprivation therapy. J Clin Endocrinol Metab. 2010;95(12):E456–E463. [PubMed]
54. De Laet C, Kanis JA, Oden A, et al. Body mass index as a predictor of fracture risk: a meta-analysis. Osteoporos Int. 2005;16(11):1330–1338. [PubMed]
55. Gonnelli S, Caffarelli C, Nuti R. Obesity and fracture risk. Clin Cases Miner Bone Metab. 2014;11(1):9–14. [PMC free article] [PubMed]
56. Zhang P, Peterson M, Su GL, Wang SC. Visceral adiposity is negatively associated with bone density and muscle attenuation. Am J Clin Nutr. 2015;101(2):337–343. [PMC free article] [PubMed]
57. Kerr D, Morton A, Dick I, Prince R. Exercise effects on bone mass in postmenopausal women are site-specific and load-dependent. J Bone Miner Res. 1996;11(2):218–225. [PubMed]
58. Maddalozzo GF, Snow CM. High intensity resistance training: effects on bone in older men and women. Calcif Tissue Int. 2000;66(6):399–404. [PubMed]
59. Vincent KR, Braith RW. Resistance exercise and bone turnover in elderly men and women. Med Sci Sports Exerc. 2002;34(1):17–23. [PubMed]
60. Carlin BI, Andriole GL. The natural history, skeletal complications, and management of bone metastases in patients with prostate carcinoma. Cancer. 2000;88(12 Suppl):2989–2994. [PubMed]
61. Alibhai SM, Duong-Hua M, Cheung AM, et al. Fracture types and risk factors in men with prostate cancer on androgen deprivation therapy: a matched cohort study of 19,079 men. J Urol. 2010;184(3):918–923. [PubMed]
62. Bober SL, Varela VS. Sexuality in adult cancer survivors: challenges and intervention. J Clin Oncol. 2012;30(30):3712–3719. [PubMed]
63. Ng E, Woo HH, Turner S, Leong E, Jackson M, Spry N. The influence of testosterone suppression and recovery on sexual function in men with prostate cancer: observations from a prospective study in men undergoing intermittent androgen suppression. J Urol. 2012;187(6):2162–2166. [PubMed]
64. Resnick MJ, Koyama T, Fan KH, et al. Long-term functional outcomes after treatment for localized prostate cancer. N Engl J Med. 2013;368(5):436–445. [PMC free article] [PubMed]
65. Kratzik CW, Lackner JE, Mark I, et al. How much physical activity is needed to maintain erectile function? Results of the Androx Vienna Municipality Study. Eur Urol. 2009;55(2):509–516. [PubMed]
66. Cormie P, Newton RU, Taaffe DR, et al. Exercise maintains sexual activity in men undergoing androgen suppression for prostate cancer: a randomized controlled trial. Prostate Cancer Prostatic Dis. 2013;16(2):170–175. [PubMed]
67. Hamilton K, Chambers SK, Legg M, Oliffe JL, Cormie P. Sexuality and exercise in men undergoing androgen deprivation therapy for prostate cancer. Support Care Cancer. 2015;23(1):133–142. [PubMed]
68. Braga-Basaria M, Dobs AS, Muller DC, et al. Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. J Clin Oncol. 2006;24(24):3979–3983. [PubMed]
69. Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120(16):1640–1645. [PubMed]
70. Nobes JP, Langley SE, Klopper T, Russell-Jones D, Laing RW. A prospective, randomized pilot study evaluating the effects of metformin and lifestyle intervention on patients with prostate cancer receiving androgen deprivation therapy. BJU Int. 2012;109(10):1495–1502. [PubMed]
71. Morote J, Gómez-Caamaño A, Alvarez-Ossorio JL, et al. The metabolic syndrome and its components in patients with prostate cancer on androgen deprivation therapy. J Urol. 2015;193(6):1963–1969. [PubMed]
72. Smith MR, Finkelstein JS, McGovern FJ, et al. Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab. 2002;87(2):599–603. [PubMed]
73. Smith MR, Lee H, McGovern F, et al. Metabolic changes during gonadotropin-releasing hormone agonist therapy for prostate cancer: differences from the classic metabolic syndrome. Cancer. 2008;112(10):2188–2194. [PMC free article] [PubMed]
74. Galvão DA, Spry N, Denham J, et al. A multicentre year-long randomised controlled trial of exercise training targeting physical functioning in men with prostate cancer previously treated with androgen suppression and radiation from TROG 03.04 RADAR. Eur Urol. 2014;65(5):856–864. [PubMed]
75. Newton RU, Taaffe DR, Spry N, et al. Can exercise ameliorate treatment toxicity during the initial phase of testosterone deprivation in prostate cancer patients? Is this more effective than delayed rehabilitation? BMC Cancer. 2012;12:432. [PMC free article] [PubMed]
76. Brown JK, Byers T, Doyle C, et al. Nutrition and physical activity during and after cancer treatment: an American Cancer Society guide for informed choices. CA Cancer J Clin. 2003;53(5):268–291. [PubMed]
77. Schmitz KH, Courneya KS, Matthews C, et al. American College of Sports Medicine roundtable on exercise guidelines for cancer survivors. Med Sci Sports Exerc. 2010;42(7):1409–1426. [PubMed]
78. Bourke L, Sohanpal R, Nanton V, Crank H, Rosario DJ, Saxton JM. A qualitative study evaluating experiences of a lifestyle intervention in men with prostate cancer undergoing androgen suppression therapy. Trials. 2012;13:208. [PMC free article] [PubMed]
79. Holzbeierlein JM, Castle E, Thrasher JB. Complications of androgen deprivation therapy: prevention and treatment. Oncology (Williston Park) 2004;18(3):303–309. discussion 310, 315, 319–321. [PubMed]
80. Moyad MA. Promoting general health during androgen deprivation therapy (ADT): a rapid 10-step review for your patients. Urol Oncol. 2005;23(1):56–64. [PubMed]
81. Spriet LL. Exercise and sport performance with low doses of caffeine. Sports Med. 2014;44(Suppl 2):S175–S184. [PMC free article] [PubMed]
82. Cornish RS, Bolam KA, Skinner TL. Effect of caffeine on exercise capacity and function in prostate cancer survivors. Med Sci Sports Exerc. 2015;47(3):468–475. [PubMed]
83. Tang BM, Eslick GD, Nowson C, Smith C, Bensoussan A. Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older: a meta-analysis. Lancet. 2007;370(9588):657–666. [PubMed]
84. Mottet N, Bastian PJ, Bellmunt J, et al. Guidelines on Prostate Cancer European Association of Urology. 2014. [Accessed June 28, 2016]. Available from: https://uroweb.org/.../1607-Prostate-Cancer_LRV3.pdf.
85. Institute of Medicine (US) Committee to Review Dietary Reference Intakes for Vitamin D and CalciumRoss AC, Taylor CL, Yaktine AL, Del Valle HB, editors. Dietary Reference Intakes for Calcium and Vitamin D. Washington (DC): The National Academies Press; 2011. [PubMed]
86. Cosman F, de Beur SJ, LeBoff MS, et al. Clinician’s Guide to Prevention and Treatment of Osteoporosis. Osteoporos Int. 2014;25(10):2359–2381. [PMC free article] [PubMed]
87. Datta M, Schwartz GG. Calcium and vitamin D supplementation during androgen deprivation therapy for prostate cancer: a critical review. Oncologist. 2012;17(9):1171–1179. [PMC free article] [PubMed]
88. Alibhai SM, Mohamedali HZ, Gulamhusein H, et al. Changes in bone mineral density in men starting androgen deprivation therapy and the protective role of vitamin D. Osteoporos Int. 2013;24(10):2571–2579. [PubMed]
89. Klein S, Burke LE, Bray GA, et al. Clinical implications of obesity with specific focus on cardiovascular disease: a statement for professionals from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism: endorsed by the American College of Cardiology Foundation. Circulation. 2004;110(18):2952–2967. [PubMed]
90. Galvão DA, Taaffe DR, Spry N, Joseph D, Newton RU. Acute versus chronic exposure to androgen suppression for prostate cancer: impact on the exercise response. J Urol. 2011;186(4):1291–1297. [PubMed]
91. Wing RR. Physical activity in the treatment of the adulthood overweight and obesity: current evidence and research issues. Med Sci Sports Exerc. 1999;31(11 Suppl):S547–S552. [PubMed]
92. Cermak NM, Res PT, de Groot LC, Saris WH, van Loon LJ. Protein supplementation augments the adaptive response of skeletal muscle to resistance-type exercise training: a meta-analysis. Am J Clin Nutr. 2012;96(6):1454–1464. [PubMed]
93. Miller PE, Alexander DD, Perez V. Effects of whey protein and resistance exercise on body composition: a meta-analysis of randomized controlled trials. J Am Coll Nutr. 2014;33(2):163–175. [PubMed]
94. Barton DL, Liu H, Dakhil SR, et al. Wisconsin Ginseng (Panax quinquefolius) to improve cancer-related fatigue: a randomized, double-blind trial, N07C2. J Natl Cancer Inst. 2013;105(16):1230–1238. [PMC free article] [PubMed]
95. FDA Announces Qualified Health Claims for Omega-3 Fatty Acids. Silver Spring (MD): US Food and Drug Administration; 2004. [Accessed March 3, 2016]. US FDA News Release P04-89. Available from: http://www.fda.gov/SiteIndex/ucm108351.htm.
96. Kris-Etherton PM, Harris WS, Appel LJ, AHA Nutrition Committee Omega-3 fatty acids and cardiovascular disease: new recommendations from the American Heart Association. Arterioscler Thromb Vasc Biol. 2003;23(2):151–152. [PubMed]
97. Oikawa S, Yokoyama M, Origasa H, et al. Suppressive effect of EPA on the incidence of coronary events in hypercholesterolemia with impaired glucose metabolism: sub-analysis of the Japan EPA Lipid Intervention Study (JELIS) Atherosclerosis. 2009;206(2):535–539. [PubMed]
98. Yokoyama M, Origasa H, Matsuzaki M, et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet. 2007;369(9567):1090–1098. [PubMed]
99. Grossmann M, Zajac JD. Hematological changes during androgen deprivation therapy. Asian J Androl. 2012;14(2):187–192. [PMC free article] [PubMed]
100. Bailey CA, Brooke-Wavell K. Optimum frequency of exercise for bone health: randomised controlled trial of a high-impact unilateral intervention. Bone. 2010;46(4):1043–1049. [PubMed]
101. Frisk J. Managing hot flushes in men after prostate cancer – a systematic review. Maturitas. 2010;65(1):15–22. [PubMed]
Articles from Research and Reports in Urology are provided here courtesy of Dove Press
Gerelateerde artikelen
- Antioxidanten: Een mix van voedingsupplementen soja, isoflavones, lycopeen, silymarin en antioxidanten - vermindert de PSA stijging significant bij prostaatkankerpatiënten na operatieve ingreep of bestraling als postoperatieve behandeling
- Capsaicin is een stofje dat veel voorkomt in rode pepers bevordert apoptosis - zelfdoding van prostaatkankercellen.
- Cranberry extract verlaagt PSA met 22,5 procent binnen een maand bij prostaatkankerpatienten die wachten op operatie blijkt uit placebo gecontroleerde studie
- Curcumine: Een half jaar dagelijks curcumine (1440 mg/dag) stabiliseert PSA progressie in vergelijking met placebo veel beter (30 vs 10 procent) bij prostaatkankerpatiënten in hormoonvrije periode copy 1
- Ellagic-acid (Quercetin-C), veel voorkomend in bessen, rode vruchten en noten geeft significant minder bijwerkingen en significant betere respons wanneer aanvullend gegeven bij chemokuren voor recidief van prostaatkanker
- Granaatappelsap onderdrukt PSA stijging bij prostaatkanker van 15 maanden naar 37 maanden dus verlenging van PSA stabiliteit met circa twee jaar
- Groene thee extract heeft uitstekend effect bij prostaatkankerpatienten in een wait-and-see programma
- Groene thee bewijst opnieuw therapeutische waarde voor prostaatkanker - 27 procent verschil in ontwikkelen van prostaatkanker tussen placebo en groene thee groepgebruik
- Knoflook, uien en sjalotten lijken de kans op het krijgen van prostaatkanker met 50% te verminderen, aldus studie NCI.
- Koffie geeft langere prostaatkanker-specifieke overleving voor specifieke subgroepen, waaronder die met het CYP1A2 AA-genotype
- Leefstijl: Drastische verandering van leefstijl en overstappen op vegetarische voeding geeft significant betere resultaten bij prostaatkankerpatiënten, die in eerste instantie reguliere aanpak weigerden
- Lezing van Dean Ornish over de combinatie van voeding, supplementen, liefde en intimiteit die leidt tot een betere gezondheid en wellicht preventief en genezend kan zijn bij kanker copy 1
- Lijnzaadolie - flax seed oil zou prostaatkanker juist stimuleren beweert dr. William P. Marley. Visolie is veel beter dan lijnzaadolie, aldus Marley
- Lycopeen, een uitstekend middel om prostaatkanker te voorkomen en progressie te remmen. En lycopeen voorkomt hart- en vaatziektes. Een wetenschappelijke analyse van arts-bioloog drs. Engelbert Valstar
- Metformin en Zyflamend, een kruidencombinatie vergelijkbaar met prostasol stopt progressie van prostaatkanker waar hormoontherapie en chemo faalden bij vier mannen met vergevorderde prostaatkanker.
- Overzichtsstudies met effecten van leefstijl, voeding en voedingstoffen als preventie van of aanvullend bij prostaatkanker en reguliere behandelingen waaronder hormoontherapie
- Plantaardig dieet vermindert kans op recidief, verbetert overleving en verbetert kwaliteit van leven door betere sexualiteit en beter plassen bij prostaatkankerpatienten
- Pomi-T, een voedingssupplement dat granaatappel, broccoli, groene thee en kurkuma bevat verlaagt PSA waarden hoog significant - 14,7 vs 78,5 procent, P = 0,0008 - in vergelijking met placebo en vermindert significant tweede reguliere behandelingen.
- Prostaatkanker patienten met een verhoogde PSA hebben baat bij verandering van levensstijl en voedingspatroon blijkt uit gerandomiseerde studie. Niemand uit groep mannen die leefstijl veranderde had later behandeling nodig. Artikel geplaatst 16 juli 2010
- Resveratrol: Elke dag glas rode wijn - resveratrol bevattend - voorkomt het ontwikkelen van prostaatkanker.
- Selenium speelt wellicht een rol in uitzaaiingsproces bij prostaatkanker blijkt uit onderzoek aan Universiteit van Wageningen.
- Studie naar effect van vitamine E in combinatie met lycopeen bij prostaatkanker in Erasmus Medisch Centrum al gestart in oktober 2004
- Vetarm dieet met vlaszaad vermindert kans op krijgen van prostaatkanker
- Vetarmdieet van Dean Ornish zorgt voor stabilisatie en zelfs teruggang van kanker bij patiënten met prostaatkanker
- Vitamine D. waarden in bloed van oudere mannen geven risico aan op krijgen van prostaatkanker. hoe lager de waarden hoe groter het risico - dubbele voor laagste waarden - bij bepaalde agressieve vormen van prostaatkanker.
- Vitamine D als aanvulling op Docetaxel - Taxotere - zorgt voor sterke vermindering van PSA-waarde bij patiënten met vergevorderde prostaatkanker.
- Vitamine D en zonlicht heeft therapeutisch en preventief effect bij prostaatkanker blijkt uit grote overzichtstudie van gerandomiseerde studies Artikel geplaatst 28 april 2009
- Vitamine E: hoge vitamine E waarden in het bloed vermindert kans op krijgen van prostaatkanker met ca. 50 procent, aldus de conclusie uit de ATBC - Alpha-Tocopherol, Beta-Carotene Cancer Prevention studie
- Selenium kan kans op prostaatkanker met meer dan 30 procent verminderen en selenium lijkt daarmee ook belangrijk in het voorkomen van een recidief of remming van primaire prostaatkanker.
- Soja isoflavonen aanvullend op bestraling bij prostaatkanker verminderen bijwerkingen en zorgen voor minder impotentie.
- Sulfurofaan vertraagt stijging van PSA tot verdubbeling met 86 procent - 28.9 vs 15.5 maanden - bij prostaatkankerpatienten na operatie in vergelijking met placebo copy 1
- Vet arm dieet plus vlaszaad heeft aantoonbaar therapeutische effect bij prostaatkanker.
- Visolie: Omega-3 vetzuren - vette vis (LC n-3) voorkomt significant prostaatkanker en vermindert significant de agressiviteit van prostaatkanker als die eenmaal is geconstateerd. Blijkt uit vergelijkende studie met 900 mannen
- Voedingsinterventie bij prostaatkankerpatienten geeft twee tegengestelde uitslagen uit twee gerandomiseerde Nederlandse studies.
- Wait and see beleid aangevuld met voeding en leefstijladviezen bij prostaatkankerpatienten voorkomt bij 80 tot 100 procent dat er nog een behandeling moet volgen.
- Voeding en voedingstoffen bij prostaatkanker. Een aantal artikelen en studies over effecten van voeding en voedingstoffen als preventie of therapeutisch bij prostaatkanker bij elkaar gezet. Update 22 juni 2010
Plaats een reactie ...
Reageer op "Overzichtsstudies met effecten van leefstijl, voeding en voedingstoffen als preventie van of aanvullend bij prostaatkanker en reguliere behandelingen waaronder hormoontherapie"